Prediction and Prevention of Type I Diabetes

$258,090U01FY2004DKNIH

Children'S Hosp Pittsburgh/Upmc Hlth Sys, Pittsburgh PA

Investigators

Linked publications & trials

Paper 39670998 Paper 39167668 Paper 39137044 Paper 39103721 Paper 38712386 Paper 38621411 Paper 37940642 Paper 37000695 Paper 36920087 Paper 36326757 Paper 36175392 Paper 35998266 Paper 35880956 Paper 35524749 Paper 35041021 Paper 34853027 Paper 34850014 Paper 34642772 Paper 34620616 Paper 34551936 Paper 34127860 Paper 33658358 Paper 33496819 Paper 33441381 Paper 33424774 Paper 33277338 Paper 32844178 Paper 32833543 Paper 32747817 Paper 32669415 Paper 32573495 Paper 32502242 Paper 32457058 Paper 32404353 Paper 32248243 Paper 32019856 Paper 32003110 Paper 31982961 Paper 31937610 Paper 31867614 Paper 31794865 Paper 31768570 Paper 31558546 Paper 31180194 Paper 31167877 Paper 30967424 Paper 30894366 Paper 30891858 Paper 30830871 Paper 30830868 Paper 30730939 Paper 30709843 Paper 30629603 Paper 30552130 Paper 30405601 Paper 30275285 Paper 30232284 Paper 30167735 Paper 30089716 Paper 30061316 Paper 30012675 Paper 29931415 Paper 29925930 Paper 29851415 Paper 29769238 Paper 29429978 Paper 29171129 Paper 29164254 Paper 29092051 Paper 29040630 Paper 29025879 Paper 28956083 Paper 28860125 Paper 28821222 Paper 28770323 Paper 28707353 Paper 28531305 Paper 28520980 Paper 28500393 Paper 28226181 Paper 28202550 Paper 28177779 Paper 28053319 Paper 27704166 Paper 27655844 Paper 27579340 Paper 27456836 Paper 27422577 Paper 27385327 Paper 27362539 Paper 27208341 Paper 27114212 Paper 26995649 Paper 26991969 Paper 26991448 Paper 26822082 Paper 26692253 Paper 26676824 Paper 26642366 Paper 26578518

Abstract

DESCRIPTION (provided by applicant) This is a submission from the Children?s Hospital and University of Pittsburgh in response to the TrialNet RFA. This group of investigators with extensive experience has formulated four specific aims that answer all the objectives of the TrialNet RFA. Specific Aim 1 extends the current oral arm of DPT-1. Specific Aim 2 proposes the use of T-cell immunology to assess the effectiveness of immune interventions in TrialNet. Specific Aim 3 addresses the important issue of psychosocial and educational needs of subjects screened and included in intervention studies. Specific Aim 4 is a pilot study of a high-affinity peptide with potential safe effectiveness for delaying or preventing progression of autoimmunity. The strength of the application is the expertise and experience of the investigators and well established collaboration across three centers.

View original record on NIH RePORTER →